论文部分内容阅读
应用双抗加心法对７８例胃癌患者血清可溶性白介素２受体（ｓＩＬ－２Ｒ）进行临床研究。结果发现：胃癌患者ｓＩＬ－２Ｒ水平明显高于胃良性疾病患者和正常人（Ｐ＜０．０１）；Ⅲ、Ⅳ期高于Ⅰ、Ⅱ期（Ｐ＜０．０５）；手术切除后（根治或姑息）ｓＩＬ－２Ｒ显著下降（Ｐ＜０．０１）；手术后复发和转移患者血清ｓＩＬ－２Ｒ升高（Ｐ＜０．０１）；如果患者血清ｓＩＬ－２Ｒ高于１０００Ｕ／ｍｌ，生存期短。提示胃癌患者ｓＩＬ－２Ｒ水平高低与肿瘤分期、手术方式、复发转移和预后有关，监测胃癌患者血清ｓＩＬ－２Ｒ水平对临床病情和预后有重大意义。
Clinical study of serum soluble interleukin 2 receptor (sIL-2R) in 78 patients with gastric cancer was performed using double-antibody plus heart method. The results showed that the levels of sIL-2R in gastric cancer patients were significantly higher than those in patients with benign gastric diseases and normal controls (P<0.01). The levels of sIL-2R in patients with gastric cancer were higher than those in stages I and II (P<0.05); Or palliative) sIL-2R was significantly decreased (P<0.01); serum sIL-2R was increased after recurrence and metastasis (P<0.01); if serum sIL-2R was higher than 1000 U/ml, survival time short. It is suggested that the level of sIL-2R in gastric cancer patients is related to tumor stage, surgical methods, recurrence metastasis, and prognosis. Monitoring serum sIL-2R levels in gastric cancer patients is of great significance for clinical condition and prognosis.